RxDoctor Payments DataLook up a doctor →

William Werschler, MD

Dermatology · Spokane, WANPI 1023119682

Payments from drug & device makers

$5,124,343in general payments, 2019–2025

Across 2,390 payments — averaging $2144.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2.4M
  • Eli Lilly$515K
  • Janssen Research & Development, LLC$423K
  • E.r. Squibb & Sons, L.L.C.$345K
  • Bausch Health US, LLC$306K
  • Aclaris Therapeutics, Inc.$222K
  • plus $877K from 42 others
$87,409in research payments, 2019–2025

Across 59 payments — averaging $1481.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ichnos Glenmark Innovation Inc$57K
  • Glenmark Pharmaceuticals Inc., USA$21K
  • Bausch Health US, LLC$9K
  • Eli Lilly$502

What the payments were for

  • Consulting fees$155,24316%
  • Speaking & faculty fees$630,94767%
  • Travel & lodging$127,35313%
  • Food & beverage$34,4314%
  • Education$4940%
  • Gifts$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,124,343 in reported general payments places this provider in the 95th percentile of 323 dermatology providers in Washington.

See all dermatology providers in Washington

Medicare billing

Part B allowed, 2024
$301,677
Medicare patients
561
Services billed
2,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$236,126
OtezlaApremilast45$215,773
Humira(Cf) PenAdalimumab17$123,920
Dupixent PenDupilumab20$74,833
Fluorouracil62$3,616
Clobetasol Propionate58$3,140
Imiquimod26$1,717
Isotretinoin11$1,585
Ketoconazole91$1,387
Metronidazole13$1,095
Triamcinolone Acetonide67$991
Tretinoin15$940
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$821
Doxycycline Hyclate29$640
Clindamycin Phosphate20$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$25,985$215,77345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 dermatology providers in Washington.

Other dermatology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →